Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study

OBJECTIVES: Thalidomide and bortezomib have been frequently used for second-line therapy in patients with myeloma relapsing after or refractory to initial melphalan-based treatment, but no randomized trials have been published comparing these two treatment alternatives. METHODS: Thalidomide- and bor...

Descripción completa

Detalles Bibliográficos
Autores principales: Hjorth, Martin, Hjertner, Øyvind, Knudsen, Lene Meldgaard, Gulbrandsen, Nina, Holmberg, Erik, Pedersen, Per Trøllund, Andersen, Niels Frost, Andréasson, Björn, Billström, Rolf, Carlson, Kristina, Carlsson, Margaretha S, Flogegård, Max, Forsberg, Karin, Gimsing, Peter, Karlsson, Torbjörn, Linder, Olle, Nahi, Hareth, Othzén, Annika, Swedin, Agneta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492844/
https://www.ncbi.nlm.nih.gov/pubmed/22404182
http://dx.doi.org/10.1111/j.1600-0609.2012.01775.x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492844/
https://www.ncbi.nlm.nih.gov/pubmed/22404182
http://dx.doi.org/10.1111/j.1600-0609.2012.01775.x

Ejemplares similares